2-arylamino pyridine, pyrimidine or triazine derivatives, preparation method and use thereof

US10377747B2 · kind B2 · utility

Assignee

• WUXI SHUANGLIANG BIOTECHNOLOGY CO., LTD. · CN

Inventors

• Jiaquan Wu · Wayland, US
• Haijun Zhang · Beijing, CN
• Huanyan Cao · Jiangyin, CN
• Shenshuang Jin · 安丰镇, CN
• Shuai Zhang · Shanghai, CN
• Zhenghua Lu · Beijing, CN
• Jian Dong · Fairfax, US
• Chengchen Wang · Jiangyin, CN
• Qiu Tan · Tianjin, CN

Key dates

• Filing date: Aug 31, 2015
• Grant date: Aug 13, 2019
• Expiry date: Aug 31, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure relates to 2-arylamino pyridine, pyrimidine, or triazine derivatives, and the preparation method and use thereof. The 2-arylamino pyridine, pyrimidine, or triazine derivatives may act on certain mutated forms of epidermal growth factor receptor, for example the L858R activating mutant, the delE746_A750 mutant, the Exonl9 deletion activating mutant, and the T790M resistance mutant, so as to be used for treatment and prevention of diseases and medical conditions. The 2-arylamino pyridine, pyrimidine, or triazine derivatives may be used for treatment and prevention of cancer. The present disclosure also relates to a pharmaceutical composition comprising 2-arylamino pyridine, pyrimidine, or triazine derivatives, intermediates useful in the manufacture of 2-arylamino pyridine, pyrimidine, or triazine derivatives, and to methods of treatment of diseases mediated by various different forms of EGFR using 2-arylamino pyridine, pyrimidine, or triazine derivatives.